Sunday, June 1, 2025
6:30 PM – 8:00 PM CT
Please note this virtually live meeting is at: 7:30 PM Eastern; 6:30 PM Central; 5:30 PM Mountain; 4:30 PM Pacific
FACULTY
 |
Craig C. Hofmeister, MD, MPH Professor, Dept of Hematology & Oncology Winship Cancer Institute of Emory University Atlanta, GA |
 |
Noopur S. Raje, MD Director, Center for Multiple Myeloma Rita Kelley Chair, Oncology Massachusetts General Hospital Cancer Center Professor of Medicine Harvard Medical School Boston, MA |
PROGRAM OVERVIEW
This program will focus on describing the mechanisms of action of current and emerging therapies in multiple myeloma and review their efficacy and safety profiles across different treatment settings. The program will also integrate patient-specific factors, prognostic indicators, and current evidence to design and implement personalized treatment plans across multiple lines of therapy. Lastly, comprehensive management strategies for patients receiving immunotherapies will be reviewed. This will include referrals to specialized treatment centers, patient and caregiver education, expected outcomes, potential complications, and proactive monitoring.
TARGET AUDIENCE
This activity is designed to meet the educational needs of academic and community hematologists/oncologists, oncology nurses, oncology nurse practitioners, physician assistants, and pharmacists to ensure the appropriate use of current and emerging therapies in relapsed/refractory multiple myeloma.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the mechanisms of action of current and emerging therapies in multiple myeloma, critically assessing their efficacy and safety profiles across different treatment settings.
- Integrate patient-specific factors, prognostic indicators, and current evidence to design and implement personalized treatment plans for patients with multiple myeloma, integrating innovative antibody and immunotherapy platforms across all lines of therapy.
- Develop comprehensive management strategies for patients with multiple myeloma receiving immunotherapies, addressing criteria and timing for referral to specialized treatment centers, patient and caregiver education on expected outcomes and potential complications, and proactive monitoring and management of unique toxicities related to treatment.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this virtually live activity for a maximum of 1.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
